Find a lawyerOur capabilitiesYour career
Locations
Our capabilities
News

Select language:

Locations
Our capabilities
News

Select language:

hamburger menu showcase image
  1. Our thinking
  2. Blogs
  3. A Fresh Take
  4. Tea on the Hill: Life Sciences and Congressional Oversight
4MIN

Tea on the Hill: Life Sciences and Congressional Oversight

Subscribe
Oct 19 2026

In this installment in our series on what companies across industries should expect from congressional investigations in 2027, we cover life sciences — an industry likely to remain a focus of oversight.

Few industries sit as squarely at the intersection of voter anxiety, political headlines, and Washington scrutiny as life sciences, and companies in the sector draw congressional attention no matter which party is in power. The political environment taking shape ahead of the 2026 midterms is different in kind, not just degree. If Democrats take the House, life sciences companies should expect a wave of investigations that move faster, reach further, and carry more legal consequences than anything the industry has seen in recent memory. Therefore, companies across the sector are best served by preparing now.

What’s in Scope: A Wide Target Set

Democrats are developing several lines of inquiry, many of which could run at the same time. Several extend beyond manufacturers to the rest of the healthcare supply chain, so a company may be drawn in as a counterparty even when it is not the target.

The affordability umbrella. Affordability is the organizing theme, and Democrats are applying it broadly. Drug pricing is the headline, but the frame extends to PBM rebate and formulary practices, GPO arrangements, insurance premiums, the effect of tariffs on drug costs, and the role of consolidation in pushing prices up. Expect executive compensation and stock performance to be set against what families pay at the pharmacy counter. Public sentiment supports the approach. Gallup’s latest reading puts the share of Americans who see big business as the country’s biggest future threat near its historic high, and Democrats are likely to channel that sentiment into public hearings and CEO testimony. 

Deals with the administration. Companies that reached agreements with the White House on pricing, domestic manufacturing, or tariff relief have created a factual record that investigators may want to examine. Most-favored-nation pricing structures, possible lobbying around those agreements, and the investment commitments attached to them are all in play. 

M&A and consolidation. Democrats may revisit life sciences transactions cleared under the current administration, with a focus on their effects on pricing and quality if they suspect an investigation or consent decree was insufficiently robust.

Private equity’s role in healthcare. Private equity ownership of nursing homes, hospital systems, and other care settings are likely to draw scrutiny, particularly roll-up acquisitions in a service line, quality of care, and the relationship between financial returns and clinical decisions. 

Federal health policy and regulatory interactions. Companies whose businesses intersected with shifts in federal health policy, including research funding, product approvals, and regulatory guidance, should expect those interactions to draw attention, as could their relationships with HHS and FDA more broadly. 

A Different Kind of Legal Exposure 

Life sciences legal teams are accustomed to agency enforcement and civil litigation. Congressional investigations follow neither set of rules, operating within their own process framework. There is no judge, no Federal Rules of Civil Procedure or Evidence, and no protective order. In practice, the committee chair acts as plaintiff, judge, and jury on questions of compliance.

Congress takes the position that it is not bound by attorney-client privilege or work-product protection and honors them only at its discretion. Documents produced to a committee can surface in a staff report, a hearing exhibit, or a press release, and once public they are available to regulators, plaintiffs, and state enforcers. Hearings are asymmetrical: witnesses can face calls to resign, and customer and investor confidence is at stake in real time. And because false statements to a committee, sworn or unsworn, carry criminal exposure, a response shaped for a political audience must still hold up as a legal document.

That is a different risk profile from an FDA warning letter or a DOJ civil investigative demand, and it calls for different preparation.

Key Takeaways

The companies that may fare best in congressional investigations are the ones that prepare before the letter arrives. Four areas deserve attention now:

  • Map your exposure. Identify which Democratic priorities touch the business: pricing practices, agreements with the administration, M&A history, private equity ownership, or regulatory interactions. Know the factual record before investigators do. 
  • Assess your document footprint. Understand what exists, where it lives, and what it says on the issues most likely to draw scrutiny, from launch-pricing analyses and pricing-committee materials to communications about administration agreements and board discussions that weigh pricing against buybacks and compensation. Gaps and surprises are far harder to manage once a subpoena is in hand. 
  • Align functions early. An effective response requires coordination across legal, government affairs, communications, and investor relations, and that coordination takes time to build. 
  • Plan for the state AG dimension. House Democrats are actively coordinating with state attorneys general, and a congressional inquiry can quickly become a parallel state enforcement matter. Build that possibility into the response strategy from the outset. 

Life sciences companies are accustomed to scrutiny. What changes in 2027 is its speed, breadth, and consequence, and the preparation that matters most happens before the first letter arrives.

To receive the latest insights on US legal developments, subscribe to the Freshfields A Fresh Take Blog.

Tags

latest political changepolitical changeadministrative and public lawcongressional investigationsglobal strategic risk managementinvestigationsmergers and acquisitionsprivate capitalprivate equityregulatory and compliance advisoryregulatory and public affairsstate attorneys generalwhite-collar defense and corporate crimelife sciences

Authors

Washington, DC

Andrew Dockham

Partner
Washington, DC, San Francisco

Nema Milaninia

Partner
New York

Jessica Heller

Counsel
Washington, DC

Loren Terry

Senior Associate
Latest Insights

Latest Insights

NAVIGATE TO
About usLocations and officesYour careerOur thinkingOur capabilitiesNews
CONNECT
Find a lawyerAlumniContact us
NEED HELP
Fraud and scamsComplaintsTerms and conditions
LEGAL
AccessibilityCookiesLegal noticesTransparency in supply chains statementResponsible procurementPrivacy

Select language:
Select language:
© 2026 Freshfields. Attorney Advertising: prior results do not guarantee a similar outcome